What question did this study set out to answer?

This research aims to evaluate the immunogenicity and tolerance of novel SARS-CoV-2 mRNA vaccine candidates.

February 11, 2026

A novel SARS-CoV-2 mRNA virus-like particle vaccine is highly potent and well tolerated in adults in a phase 1 randomized clinical trial.

Key Points

This research aims to evaluate the immunogenicity and tolerance of novel SARS-CoV-2 mRNA vaccine candidates.
Developed two candidate vaccines using mRNA technology and virus-like particles.
Conducted a phase 1 randomized clinical trial with adult participants.
Compared the immunogenicity and tolerance of the new vaccines against a licensed mRNA vaccine.
AZD6563 demonstrated similar immunogenicity to BNT162b2 at one third the dosage (10 μg versus 30 μg).
Both candidate vaccines were well tolerated compared to the licensed vaccine.

Abstract

By combining mRNA vaccine technology with VLP-based antigen display, we developed two candidate SARS-CoV-2 vaccines, AZD9838 and AZD6563, that were well tolerated versus a licensed mRNA vaccine, BNT162b2. Furthermore, the variant-matched AZD6563 generated a similar immunogenicity to BNT162b2 but at one third of the dosage (10 μg versus 30 μg).

Bookmark

Cite This Study

Rego et al. (Sat,) studied this question.

synapsesocial.com/papers/698c1bdc267fb587c655ddd8 https://doi.org/https://doi.org/10.1016/j.vaccine.2026.128304

Bookmark